Physician profile

Perry Lopez

Corneal and Contact Management · Indianapolis, IN

NPI 1922192731

$44,001.37

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$237.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Maculogix, INC. $30,676.48 2019-2020
Coopervision INC. $12,763.89 2019-2024 Myday Contact Lens
Alcon Vision LLC $350.08 2021-2023 Dailies Total1
Abbvie INC. $79.93 2022
Lombart Brothers, INC. $72.49 2019-2020
Bausch & Lomb, A Division of Bausch Health US, LLC $20.76 2019
Shire North American Group INC $20.45 2019
Abb Con-Cise Optical Group LLC $17.29 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Perry Lopez

$44,001.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Maculogix, INC.

https://glasscript.com/doctor/418338/perry-lopez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.